CDSCO approves Boehringer Ingelheim’s Jardiance for treating heart failure
It's the first treatment for heart failure with preserved ejection fraction (HFpEF) in India
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Jardiance
FDA approves Eli Lilly drug to cut death and hospitalisation risk in all heart patients
The drug was approved last year for some adults living with heart failure with reduced ejection fraction, which happens when the…
Boehringer Ingelheim launches additional heart failure indication for Jardiance in India
Empagliflozin - the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death, in people with type-II…
US FDA approves Jardiance to treat adults living with heart failure with reduced ejection fraction
Heart failure accounts for more than one million hospitalisations a year in the US
European Commission approves Jardiance to treat heart failure
This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 per cent reduction in the combined…
Global diabetes therapeutic market has grown sixfold in last two decades: GlobalData
The market has been a lucrative space for drug developers, as the disease is highly prevalent and patient numbers are expected to…
SGLT-2 inhibitors may primarily drive growth of branded heart failure treatment market: GlobalData
Approximately 55 per cent of type T2D patients suffer from cardiovascular disease (CVD), which often leads to further…